Chicago, March 31, 2025 /PRNewswire/ – SparX Biopharmaceutical Corp (“SparX”), a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, today announced the signing of
Chicago, USA – SparX Biopharmaceutical Corp. announced today that it will present clinical updates on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody, during the Trial-in-Progress poster session at the 2025 American Association for Cancer Research (AACR) Annual Meeting on April 28, from 2:00 PM to 5:00 PM.
Chicago, USA – SparX is thrilled to officially unveil its groundbreaking Nano Antibody Bifunctional Biparatopic Antibody Drug Conjugate (Nab2-ADC), a pioneering development poised to revolutionize
Chicago, USA – Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has
Chicago, USA – Signifying a monumental step forward in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces that its Investigational New Drug
Chicago, USA – Signifying a monumental step forward in the domain of powered antibody therapies, the SparX Group is thrilled to unveil its strategic alliance
Chicago, USA – Making significant strides in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. is thrilled to announce its Investigational New Drug (IND)
Press Release Sparx Biopharmaceutical Welcomes Dr. Roland Meier as Chief Medical Officer Chicago, USA — Spearheading the field of powered antibody therapies, SparX Biopharmaceutical Corp.
With a mission of “Bolstering human immunity by utilizing empowered antibody therapies”, the SparX Group announced that the FDA has approved their IND application for
August 10th, 2021 Sparx Therapeutics, an emerging biopharmaceutical company specializing in developing multi-specific antibody and antibody-drug conjugate (ADC) drugs, today announced the appointment of Ms. Juxiang
Chicago，USA September 1, 2020 Sparx Therapeutics, an emerging biopharmaceutical company specializing in developing multi-specific antibodies to treat solid tumors, today announced the appointment of Dr.
Sparx Therapeutics & KPC Pharmaceutical Sign Agreement for the Development of anti-Claudin 18.2 Antibodies Sparx Therapeutics, Inc. has signed an agreement with KPC Pharmaceutical to
China, Sep-10-2018 Central South University Xiangya – Yaoyuan Pharma Precision Medicine Research Center has just been officially founded today. This is yet another newly established
